Home
VRDN
VRDN News

Latest Viridian Therapeutics Inc. (VRDN) News on October 15, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

12 days ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Business Wire

4 months ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Business Wire

5 months ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Business Wire

5 months ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Business Wire

5 months ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Business Wire

6 months ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

8 months ago

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire

8 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Business Wire

9 months ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?

Simply Wall St.

10 months ago

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?

Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints

TipRanks

10 months ago

Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints

Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen

Investor's Business Daily

10 months ago

Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Investor's Business Daily

10 months ago

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Business Wire

10 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Business Wire

10 months ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Business Wire

a year ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings

Simply Wall St.

a year ago

Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Business Wire

a year ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Business Wire

a year ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Business Wire

a year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Business Wire

a year ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Business Wire

a year ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Business Wire

a year ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Business Wire

a year ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Business Wire

a year ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Business Wire

a year ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

GuruFocus.com

a year ago

Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements

GuruFocus.com

a year ago

Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Business Wire

a year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Business Wire

a year ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Business Wire

2 years ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

2 years ago

Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire

2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Business Wire

2 years ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Investing.com

2 years ago

Dow futures rebound after Fed-inspired losses; tech earnings in spotlight

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Barrons.com

2 years ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Analysts Have Made A Financial Statement On First Busey Corporation's (NASDAQ:BUSE) Annual Report

Simply Wall St.

2 years ago

Analysts Have Made A Financial Statement On First Busey Corporation's (NASDAQ:BUSE) Annual Report

Virtu Financial (VIRT) Q4 Earnings Miss on Higher Expenses

Zacks

2 years ago

Virtu Financial (VIRT) Q4 Earnings Miss on Higher Expenses

Business Wire

2 years ago

Hamilton Insurance Group, Ltd. to Report Fourth Quarter 2023 Financial Results on March 6, 2024

GuruFocus.com

2 years ago

First Busey Corp (BUSE) Reports Mixed Q4 Earnings Amid Strategic Acquisitions and Balance Sheet ...

DuPont Stock Plunges on Lousy Guidance. Blame China and ‘Destocking.’

Barrons.com

2 years ago

DuPont Stock Plunges on Lousy Guidance. Blame China and ‘Destocking.’

Compared to Estimates, First Busey (BUSE) Q4 Earnings: A Look at Key Metrics

Zacks

2 years ago

Compared to Estimates, First Busey (BUSE) Q4 Earnings: A Look at Key Metrics

Grow Financial Federal Credit Union Streamlines, Enhances Self-Service Banking Through NCR Atleos Partnership

Business Wire

2 years ago

Grow Financial Federal Credit Union Streamlines, Enhances Self-Service Banking Through NCR Atleos Partnership

Investing.com

2 years ago

Coinbase Global cut at JPMorgan amid Bitcoin ETF skepticism: 4 big analyst cuts

Hamilton Appoints Jamie Secor as Chief Underwriting Officer of US E&S Insurer Hamilton Select

Business Wire

2 years ago

Hamilton Appoints Jamie Secor as Chief Underwriting Officer of US E&S Insurer Hamilton Select

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Business Wire

2 years ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Business Wire

2 years ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Q3 Traditional Fast Food Earnings: Arcos Dorados (NYSE:ARCO) Impresses

StockStory

2 years ago

Q3 Traditional Fast Food Earnings: Arcos Dorados (NYSE:ARCO) Impresses

Howard Hughes, Carrier, and More Stocks See Action From Activist Investors

Barrons.com

2 years ago

Howard Hughes, Carrier, and More Stocks See Action From Activist Investors

Newsfile

2 years ago

Equinox Gold Produces 564,500 Ounces of Gold in 2023, Reports 155,000 Ounces of Gold Produced in Fourth Quarter

Is It Too Late To Consider Buying CSG Systems International, Inc. (NASDAQ:CSGS)?

Simply Wall St.

2 years ago

Is It Too Late To Consider Buying CSG Systems International, Inc. (NASDAQ:CSGS)?

Tiger Woods Breaks Up With Nike. Will On Holding Be His New Home?

Motley Fool

2 years ago

Tiger Woods Breaks Up With Nike. Will On Holding Be His New Home?

Shareholders in National Vision Holdings (NASDAQ:EYE) are in the red if they invested three years ago

Simply Wall St.

2 years ago

Shareholders in National Vision Holdings (NASDAQ:EYE) are in the red if they invested three years ago

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?

Simply Wall St.

2 years ago

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Business Wire

2 years ago

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Enovix and Group14 Announce Collaboration to Develop Best-in-Class Silicon Batteries

GlobeNewswire

2 years ago

Enovix and Group14 Announce Collaboration to Develop Best-in-Class Silicon Batteries

3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond

Motley Fool

2 years ago

3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond

Intellia to lay off staff, cut some early research

BioPharma Dive

2 years ago

Intellia to lay off staff, cut some early research

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

2 years ago

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Time to Buy These Top-Rated Security and Safety Services Stocks

Zacks

2 years ago

Time to Buy These Top-Rated Security and Safety Services Stocks

15 Best Earthquake Insurance Companies Heading into 2024

Insider Monkey

2 years ago

15 Best Earthquake Insurance Companies Heading into 2024

Salesforce upgraded, Chipotle downgraded: Wall Street's top analyst calls

The Fly

2 years ago

Salesforce upgraded, Chipotle downgraded: Wall Street's top analyst calls

Is M/I Homes, Inc.'s (NYSE:MHO) Latest Stock Performance A Reflection Of Its Financial Health?

Simply Wall St.

2 years ago

Is M/I Homes, Inc.'s (NYSE:MHO) Latest Stock Performance A Reflection Of Its Financial Health?

Do WaFd's (NASDAQ:WAFD) Earnings Warrant Your Attention?

Simply Wall St.

2 years ago

Do WaFd's (NASDAQ:WAFD) Earnings Warrant Your Attention?

Business Wire

2 years ago

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

These 8 Winning Bank Stocks Are 12% of My Portfolio. Here Is What I Think About All of Them.

Motley Fool

2 years ago

These 8 Winning Bank Stocks Are 12% of My Portfolio. Here Is What I Think About All of Them.

13 Penny Stocks that Captured the Attention of Billionaires

Insider Monkey

2 years ago

13 Penny Stocks that Captured the Attention of Billionaires

Victor Joseph Promoted to President & Chief Operating Officer of Mercury General Corporation

PR Newswire

2 years ago

Victor Joseph Promoted to President & Chief Operating Officer of Mercury General Corporation

Wall Street Analysts Think Afya (AFYA) Is a Good Investment: Is It?

Zacks

2 years ago

Wall Street Analysts Think Afya (AFYA) Is a Good Investment: Is It?

Should You Buy Tennant Company (NYSE:TNC) For Its Upcoming Dividend?

Simply Wall St.

2 years ago

Should You Buy Tennant Company (NYSE:TNC) For Its Upcoming Dividend?

Viator Partners with Thoughtworks to Scale Power of Platforms to Enhance Traveler Experiences

Business Wire

2 years ago

Viator Partners with Thoughtworks to Scale Power of Platforms to Enhance Traveler Experiences

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Business Wire

2 years ago

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Equinox Gold's Greenstone Project: 96% Complete, Commissioning Underway

Newsfile

2 years ago

Equinox Gold's Greenstone Project: 96% Complete, Commissioning Underway

Business Wire

2 years ago

Grindr Brings Free At-Home HIV Self-Test Kits to Europe for the First Time With New Programs in Georgia and Ireland

Oil Price Tumbles Below $75 With Production at Record Levels

Zacks

2 years ago

Oil Price Tumbles Below $75 With Production at Record Levels

Xenia Hotels & Resorts Declares Dividend For Fourth Quarter 2023 And Announces Board Approval For A $100 Million Increase In Share Repurchase Program

PR Newswire

2 years ago

Xenia Hotels & Resorts Declares Dividend For Fourth Quarter 2023 And Announces Board Approval For A $100 Million Increase In Share Repurchase Program

Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress

GuruFocus.com

2 years ago

Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress

GuruFocus.com

2 years ago

Grindr Inc (GRND) Reports 39% Revenue Surge in Q3 2023, Ups Full-Year Outlook

Business Wire

2 years ago

Grindr Inc. Reports Third Quarter 2023 Revenue Growth of 39%, Raises Guidance

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Business Wire

2 years ago

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Business Wire

2 years ago

Grindr Names Tolu Adeofe as Director of Investor Relations As It Approaches One Year Anniversary of its NYSE Listing

SFL - Third Quarter 2023 Results Presentation

GlobeNewswire

2 years ago

SFL - Third Quarter 2023 Results Presentation

Share on Social Networks: